Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Eyelashes – ptosis
(2005): Casson RJ+, Am J Ophthalmol 139(5), 932
Eyelid burning (1.1%)
Eyelid edema (1–4%)
(2001): Stewart WC+, Am J Ophthalmol 131(5), 631
Eyelid erythema (1–4%)
(2006): Lai CH+, Eur J Ophthalmol 16(4), 627
Eyelid pain (0.4%)
Eyelid pigmentation
(2006): Inoue K+, Nippon Ganka Gakkai Zasshi 110(8), 581
(2003): Herndon LW+, Am J Ophthalmol 135(5), 713
(2001): Wand M+, Arch Ophthalmol 119(4), 614
(2000): Kook MS+, Am J Ophthalmol 129, 804
Eyelid pruritus (1.7%)
Eyelid stinging (0.4%)
Iris pigmentation
(2006): Jpn J Ophthalmol 50(2), 96 (50%)
(2006): Inoue K+, Nippon Ganka Gakkai Zasshi 110(8), 581
(2005): Chiselita D+, Oftalmologia 49(3), 39
Macular edema
(2005): Altintas O+, Eur J Ophthalmol 15(1), 158
Ocular edema
(2005): Arcieri ES+, Arch Ophthalmol 123(2), 186
Ocular erythema
Ocular herpes simplex
(2001): Morales J+, Am J Ophthalmol 132(1), 114 (2 cases)
Ocular pigmentation (5%)
(2004): Grierson I+, Jpn J Ophthalmol 48(6), 602
(2002): Novack GD+, JAmGeriatrSoc50(5), 956
(2002): Stjernschantz JW+, Surv Ophthalmol 47(Suppl 1), S162
(2001): Aung T+, Am J Ophthalmol 131(5), 636
(2001): Netland PA+, Am J Ophthalmol 132(4), 472 (5.2%)
(2001): Stewart WC+, Am J Ophthalmol 131(5), 631
(2000): Alm A+, Acta Ophthalmol Scand 78, 71
(2000): Camras CB+, JGlaucoma9, 95
(1999): Hejkal TW+, Semin Ophthalmol 14, 114
(1997): Bito LAZ, Surv Ophthalmol 41(Suppl 2), S1
(1997): Wistrand JP+, Surv Ophthalmol 41(Suppl 2), S129
Ocular stinging
(2004): Fechtner RD+, Acta Ophthalmol Scand 82(1), 42
Uveitis (1%)
(2005): Cano Parra J+, Arch Soc Esp Oftalmol 80(3), 137
(2003): Costagliola C+, Expert Opin Pharmacother 4(10), 1775
(1999): Smith SL+, Acta Ophthalmol Scand 77(6), 668 (1%)
(1998): Fechtner RD+, Am J Ophthalmol 126(1), 37
Other
Gynecomastia (0.2%)
Myalgia/Myositis/Myopathy/Myotoxicity (1–10%)
LAVENDER
Scientific names: Lavandula angustifolia; Lavandula dentata;
Lavandula spica; Lavandula vera
Family: Lamiaceae
Trade and other common names: Alhucema; English
Lavender; French Lavender; Spanish Lavender; Spike Lavender
Category: Anxiolytic
Purported indications and other uses: Restlessness, insomnia,
loss of appetite, flatulence, colic, giddiness, nervous headache,
migraine, toothache, sprains, neuralgia, rheumatism, acne,
pimples, nausea, vomiting. Flavoring, fragrance, insect repellent
Half-life: N/A
Reactions
Skin
Dermatitis
(2002): Schempp CM+, Hautarzt 53(2), 93
(1999): Coulson IH+, Contact Dermatitis 41(2), 111
Other
Gynecomastia
(2007): Dean CJ, NEnglJMed356(24), 2543
(2007): Henley DV+, NEnglJMed356(5), 479
(2007): Kalyan S, NEnglJMed356(24), 2542
LEFLUNOMIDE
Trade name: Arava (Sanofi-Aventis)
Indications: Rheumatoid arthritis
Category: Disease-modifying antirheumatic; Tyrosine kinase
inhibitor
Half-life: 14–15 days
Clinically important, potentially hazardous interactions
with: warfarin
Reactions
LEFLUNOMIDE 321
Skin
Acne (1–10%)
Allergic reactions (sic) (2%)
(2000): Smolen JS+, Rheumatology (Oxford) 39 (Suppl 1), 48
(1999): Goldenberg MM, Clin Ther 21, 1837
(1997): Silva Junior HT+, Am J Med Sci 313, 289
(1995): Mladenovic V+, Arthritis Rheum 38, 1595
Bullous dermatitis
(2003): Canonne-Courivaud D+, Ann Dermatol Venereol
130(4), 435
(2000): Lepine G, Rock Hill, SC (6 months after starting drug)
(from Internet) (observation)
Dermatitis (1–10%)
Dermatomyositis
(2005): Gomez Rodriguez N+, An Med Interna 22(6), 300
Diaphoresis (1–10%)
Eczema (2%)
Erythema multiforme
(2003): Fischer TW+, Dermatology 207(4), 386
Exfoliative dermatitis
(2003): Bandyopadhyay D, JDermatol30(11), 845
Herpes (1–10%)
Herpes zoster
(2006): Wolfe F+, Rheumatology (Oxford) 45(11), 1370
Lichenoid eruption
(2004): Rivarola de Gutierrez E+, Dermatology 208(3), 232
(photodistributed)
(2003): Canonne-Courivaud D+, Ann Dermatol Venereol
130(4), 435
Lupus erythematosus
(2005): Chan SK+, Clin Exp Dermatol 30(6), 724
(2005): Elias AR+, Cutis 76(3), 189
(2005): Gensburger D+, Ann Rheum Dis 64(1), 153
(2005): Goeb V+, Rheumatology (Oxford) 44(6), 823
(2004): Kerr OA+, Clin Exp Dermatol 29(3), 319
Nodular eruption (1–10%)
Peripheral edema (1–10%)
Pigmentation (1–10%)
Pruritus (4%)